• Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
  • Log In
    • Register
Contacts us @ MediPr.org
Medical News Asia | Powered by ['mediPr]
  • MDnews
  • About [‘mediPr]
  • HER2 Explorer
  • TROP Tool
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Scroll to next section Scroll to next section
Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail


MEDICAL NEWS ASIA

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

By: scienterrific | Last updated: 4 December 2018 | In: Medical News Asia, Oncology, Surgery

Article Keywords

NovusScientific, resorbable mesh, surgical matrix, surgical mesh, synthetic mesh, TIGR, hernia

UPPSALA, Sweden, Dec. 4, 2018 /PRNewswire/ — Onlay mesh placement of the synthetic and fully resorbable TIGR®Matrix surgical mesh (Novus Scientific AB, Uppsala — Sweden) for the prevention of incisional hernia in septic patients undergoing emergency laparoscopy showed encouraging efficacy and safety in a small retrospective study, as presented during the XXVIII Waterford Surgical October Club Meeting.

Approximately one in three patients undergoing emergency laparotomy develop an incisional hernia. A recent, major paradigm shift in abdominal closure is onlay surgical mesh insertion as a prophylactic measure to prevent incisional hernia at the initial operation or completion of a temporary abdominal closure. However, conceptual difficulties complicate such procedure in patients with sepsis.

Lead author Michael Moore and colleagues presented a small retrospective case series in six septic patients undergoing onlay mesh placement with TIGR®Matrix surgical mesh post-emergency laparotomy at a single institution.

The TIGR®Matrix resulted in a low complication rate. No post-procedural incisional hernias were reported, and no patients developed a seroma. One patient was reported to have a wound infection.

Onlay TIGR®Matrix surgical mesh placement in septic patients undergoing emergency laparoscopy is encouraging, concluded the investigators of the Letterkenny University Hospital. A long-term follow-up is required to validate these results.

About the TIGR®Matrix

TIGR®Matrix is the first long-term resorbable, 100% synthetic, surgical mesh. Its unique technology consisting of dual-stage degradation and full resorption, paired with ease of use, is a significant step forward in surgical mesh technology.

The fast-degrading part improves the meshes’ flexibility and stretchability, provides extra strength during the immediate healing phase, and gradually absorbs during the first four months. The slow-degrading part of the mesh provides optimal strength for up to nine months with complete resorption in approximately three years. TIGR®Matrix uses 100% synthetic polymers that are well documented, clinically proven, and commonly used in medical devices since the 1970s.

About the Novus Scientific

Novus Scientific AB (www.novusscientific.com) develops, manufactures and markets resorbable implants that help the body’s own healing.

The headquarter, research and production facilities are located in Uppsala, Sweden.

Source

Moore M, et al. Prevention of incisional hernia post emergency laparotomy:
A time to change? A case series. Presented at the XXVIII Waterford Surgical October Club Meeting, 13 October 2018.


Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

YOU MAY ALSO LIKE

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2018 MediPaper Medical Communications Ltd. – TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail

YOU MAY ALSO LIKE

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

© Copyright 2018 MediPaper Medical Communications Ltd. – TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

Categories

Categories

Newsletter


 [‘mediPr] | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | CORTiX AI for Medical Science | Dub-Dub Subtitle Generation
© 2016-2026 MediPaper Medical Communications Ltd. | Website by [’mediPr] Sydney | Singapore | Hong Kong | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
Link to: Efficacy of oral Cladribine for MS durable after a two-year treatment course Link to: Efficacy of oral Cladribine for MS durable after a two-year treatment course Efficacy of oral Cladribine for MS durable after a two-year treatment cours... Link to: MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab Link to: MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles...
Scroll to top Scroll to top Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings×

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

5
Accept settingsHide notification only